SHANGHAI, Nov. 23, 2022 – WuXi Biologics (“WuXi Bio”) (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), received the 2022 “Prime Employers for Women” silver award at a recent ceremony held by sHero, a non-profit organization dedicated to the development and growth of women. The company was cited for its excellent performance in creating greater Diversity, Equity and Inclusion (DE&I) in the workplace.
WuXi Biologics was also profiled in the 2022 DE&I China Best Practices Guide (“the Guide”) for its efforts in promoting DE&I across the company through enriching initiatives and activities. The Guide – jointly published by sHero and Michael Page, a leading professional recruitment agency – features best-practice cases of 30 well-known global companies from various industries such as Ford and SONY Group to help more organizations rise to a greater level of diversity, equity and inclusion in their own work environments.
Dr. Chris Chen, CEO of WuXi Biologics, said, “DE&I, as a vital component of ESG (Environment, Social, Governance), is of great importance to drive forward the continuous innovation and sustainable development of WuXi Biologics. We are very honored to receive the silver award of ‘Prime Employers for Women’ in 2022 and selected for inclusion in the Guide, which we view as a testimony to the success of our DE&I efforts and ESG strategy. We have integrated DE&I into our PROUD culture to encourage employees to constantly pursue career growth and success. With DE&I and ESG initiatives as a cornerstone of our global business development, and rooted in our mission and vision, we will continue to enable our partners to benefit patients worldwide.”
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy. The company is committed to creating a safe, harmonious, and inclusive working environment and an equitable workplace.
There are 10,000+ employees from over 10 countries working at WuXi Biologics. Women hold 53% of all full-time positions, and 53% of those are in STEM (Science, Technology, Engineering, Mathematics) positions, which is much higher than the industry average. In addition, the company has exceeded its target of having over 45% female managers. In 2022, a global WiSTEM (Women in STEM) program was launched across all WuXi Biologics sites to encourage female employees to pursue both professional development and personal growth.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2022, WuXi Biologics is supporting 534 integrated client projects, including 14 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com